ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Real-world challenges in primary central nervous system lymphoma: a case series.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary central nervous system lymphoma (PCNSL) belongs to the group of the large B-cell lymphomas of immune-privileged sites, confined to the central nervous system. Its heterogeneous clinical and radiological presentation often leads to diagnostic delay, particularly in non-specialized centers. This study aimed to characterize the clinical, demographic, imaging, and treatment-related features of patients diagnosed with PCNSL in a tertiary hospital without the needed facilities to manage these patients and to highlight associated diagnostic challenges.
methodsWe performed a retrospective, descriptive, single-centre study including patients diagnosed with histologically confirmed PCNSL between February 2011 and December 2022. Clinical, laboratory, imaging, histology of brain biopsy, treatment, and survival data were collected and analysed. Survival time was defined as the interval from diagnosis to death, and symptom-to-diagnosis time as the interval from symptom onset to pathological confirmation.
resultsTwenty-two patients were included (median age 65 years), most of whom were immunocompetent (82%). Neuropsychiatric symptoms and focal neurological deficits were the most common presentations. Imaging revealed predominantly supratentorial (82%) and multifocal (68%) lesions, with homogeneous gadolinium enhancement in most cases and universal diffusion restriction on MRI. Atypical imaging patterns, including ring enhancement in immunocompetent patients, were observed. Histological confirmation was achieved in 21 cases; cerebrospinal fluid flow cytometry was diagnostic in only two patients with spinal or leptomeningeal involvement. Median symptom-to-diagnosis interval was 2.5 months. Younger patients (< 50 years) had longer diagnostic delays but significantly longer survival. Patients receiving targeted therapy had significantly longer median survival than those receiving palliative care (7 vs. 1 month). Overall median survival was 2 months, and six-month mortality was 54.5%.
conclusionPCNSL remains a major diagnostic challenge, particularly in non-specialized hospitals, due to its clinical and radiological heterogeneity. Early suspicion, prompt biopsy, and timely referral to specialized centers are crucial to improve outcomes. Although limited by the small sample size and retrospective design, this study provides relevant real-world data highlighting the impact of diagnostic delay and treatment access on survival.
Indexed as
Identifiers
42026336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.